Ray et al. demonstrated that the combination of citarinostat with anti-programmed death ligand-1 (PD-L1) antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma [25], whereas the combination of Alpha-Enolase (ENO1) inhibitor and citarinostat enhances autologous MM-specific CD8+ cytotoxic T lymphocyte activity [26]. The gene discussed is CD8A; the disease is neoplasm.